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ABSTRACT
Among the many different structurally distinct classes of b-lactams, the carbapenem class is regarded as
that which is most potent and which has the widest spectrum of antimicrobial activity. Rapidly
bactericidal, and demonstrating time-dependent killing, carbapenemes have a spectrum of antimicrobial
activity that includes Gram-positive and Gram-negative aerobic and anaerobic pathogens. Their in-vitro
activity includes extended-spectrum b-lactamase (ESBL)-producing pathogens and carbapenems are
currently considered to be the treatment of choice for serious infections due to ESBL-producing
organisms. However, isolates acquiring resistance under treatment have been reported. Imipenem,
meropenem and ertapenem are licensed in the European Community and panipenem and biapenem are
also available in Japan and South Korea. Other carbapenemes are under development.
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INTRODUCTION
Thienamycin was found to be highly active
against a variety of isolates [1]. The ‘carbapenem
story’ started with the detection of thienamycin in
the laboratories of Merck, Sharp & Dohme (NJ,
USA), from a culture of Streptomyces cattleya,
which was isolated by Compan˜ia Espan˜ola de la
Penicillinia y Antibioticos [2] but was extremely
unstable and efforts were made to develop a more
stable compound. The result of this was the ﬁrst
carbapenem to be licensed for clinical use, namely
imipenem.
Among the many different structurally distinct
classes of b-lactams, the carbapenem class is
considered to be the most potent and to have
the widest spectrum of antimicrobial activity.
Carbapenems are rapidly bactericidal, and dem-
onstrate time-dependent killing. Their spectrum
of antimicrobial activity includes Gram-positive
and Gram-negative aerobic and anaerobic patho-
gens. Their in-vitro activity includes the ex-
tended-spectrum b-lactamase (ESBL)-producing
pathogens, which are increasingly being reported
from different parts of the world. A comprehen-
sive account of carbapenems has been written by
Bryskier [3].
Imipenem was licensed in 1984 in Germany. It
was more than 10 years before a second carbape-
nem, meropenem, was licensed in 1995, while
ertapenem was licensed by the European Com-
munity in 2002. In Japan and South Korea,
panipenem and biapenem are also available.
Other carbapenems, e.g., doripenem and CS-023
(R-115685), are still under development, and at
the time of the conference were not licensed in
any country. This article reviews the key attri-
butes of licensed carbapenems and modiﬁes the
proposed classiﬁcation scheme for the carbape-
nem class to include future compounds [4].
MICROBIOLOGY
Carbapenems are active against many clinically
important pathogens and are particularly stable to
a wide variety of b-lactamases (including the
ESBLs and AmpC-type enzymes). As a conse-
quence, they retain activity against a wide variety
of multiply resistant pathogens, especially ceph-
alosporin-resistant Gram-negative bacteria. This
is of importance, as the incidence of strains
expressing ESBLs (and often more than one ESBL
per organism) is increasing [5–8]. For example,
the Paul-Ehrlich-Society’s multicentre survey on
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resistance, which has been conducted on a regular
basis since 1975, reported, for the years 2001 and
2004, ESBL phenotypes in 1.8% and 5.1% of
Escherichia coli, in 12.7% and 7.3% of Klebsiella
pneumoniae, and in 5.3% and 12.4% of Klebsiella
oxytoca isolates, respectively [9].
Imipenem, meropenem and ertapenem are
generally considered to be equally active against
most Gram-negative and Gram-positive patho-
gens [10–12]. However, there are subtle differ-
ences, depending partly on the b-lactamase
produced by the organisms.
In 2001, Livermore et al. reported differences in
activity between ertapenem and imipenem
against Klebsiella isolates in relation to b-lactamase
proﬁles. The MIC50 and MIC90 of ertapenem for
ESBL producers were 0.03 and 0.06 mg ⁄L, respec-
tively, whereas those of imipenem were 0.12 and
0.5 mg ⁄L, respectively. Table 1 gives the distri-
bution of strains inhibited at various concentra-
tions [13]. Livermore et al. also investigated
inoculum effects on MIC. They reported that the
maximum inoculum effect with ertapenem for an
ESBL producer was eight-fold and that most
effects were four-fold or less; effects with imipe-
nem were unrelated to ESBL production and were
slightly greater than those with ertapenem.
A K. pneumoniae strain that produced a carbape-
nemase (IMP-1 enzyme), but lacked an outer-
membrane porin, was highly resistant to both
ertapenem and imipenem (MIC >32 mg ⁄L).
A variant of the same strain that retained the
carbapenemase but regained porin expression
was more susceptible to imipenem (MIC 2 mg ⁄L)
and ertapenem (MIC 6 mg ⁄L). Ertapenem was
found to be slightly less stable in the presence of
b-lactamase than imipenem. Kiffer et al. [14]
compared the pharmacodynamic potencies of
imipenem, meropenem and ertapenem—mea-
sured as percentage of dosing interval during
which free drug was above the MIC and modelled
via a 5000-subject Monte-Carlo simula-
tion—against 133 ESBL-producing isolates. They
also predicted that ertapenem was slightly less
effective than imipenem or meropenem. Colodner
et al. [29] from Israel reported that imipenem was
the most active carbapenem against ESBL pro-
ducers, followed by meropenem, with ertapenem
being the least active.
Resistance to carbapenems has been reported in
many species of Gram-negative bacilli [15–29] In
1999, Martinez-Martinez et al. [15] reported that,
in two clinical isolates of ESBL-producing
K. pneumoniae, resistance to carbapenems was
due to porin loss and the presence of these b-
lactamases. Lee et al. claim to be the ﬁrst to report
reduced carbapenem susceptibility in K. pneumo-
niae strains due to combined DHA b-lactamases
(discovered at Dhahran) production and porin
loss [30]. Woodford et al. from the UK conﬁrmed
ertapenem resistance in 95 Klebsiella spp. and 76
Enterobacter spp. sent to their reference centre [31].
These had combinations of ESBLs or AmpC and
impermeability. Only 8% of the Klebsiella spp.and
32% of the Enterobacter spp. were resistant to
imipenem, and 26% of both species were resistant
to meropenem. According to Woodford et al., the
differential susceptibility to carbapenems war-
rants further investigation and ‘may reﬂect rela-
tive penetration rates through minor porins,
differential susceptibility to efﬂux or relative
susceptibility to slow hydrolysis by AmpC en-
zymes or ESBLs’ [31]. A report from Spain, where
Hernandez et al. found 8% imipenem resistance
in Salmonella enterica from chicken, is alarming
[32]. All previously licensed carbapenems are
clinically inactive against methicillin-resistant
staphylococci, but a newer analogue (CS-023;
Sankyo, Tokyo, Japan) is active in vitro against
such isolates [33].
Of clinical interest is the selection of carbape-
nem non-susceptible mutants under treatment.
The ﬁrst report I am aware of was published from
France by Mainardi et al. in 1997 [34]. They
cultured an imipenem-resistant strain of Citrob-
acter freundii that did not produce carbapenemase,
and the authors concluded that the resistance was
Table 1. MICs for extended-spectrum b-lactamase-pro-
ducing Klebsiella
MIC (mg ⁄L)
Number of isolates inhibited
Ertapenem Imipenem
0.007 8
0.015 49
0.03 71
0.06 39 14
0.12 9 125
0.25 22
0.5 2 15
1 1 4
2 1 1
4
8 1
Data from [12,13].
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associated with reduced porin-mediated perme-
ability with high-level cephalosporinase produc-
tion. Since then, similar anecdotal case reports of
carbapenem resistance selected under carbape-
nem treatment have been published by several
authors, concerning imipenem and meropenem
[35], imipenem [36], meropenem [37], ertapenem
and meropenem [38], imipenem and meropenem
[39], and ertapenem [40].
PHARMACOKINETIC PROPERTIES
Imipenem and panipenem are subject to degra-
dation by dehydropeptidase-I, a renal tubular
enzyme, and are thus co-administered with a
dehydropeptidase-I inhibitor, cilastatin or bet-
amipron. Meropenem, biapenem and ertapenem
are more stable and do not require protection
from dehydropeptidase-I.
Table 2 gives the pharmacokinetic parameters
of the compounds. The urinary excretion rates
varies from 30% for panipenem to 70% for
imipenem and meropenem [41–45]. The lowest
rates of protein binding, namely 4%, are reported
for panipenem and biapenem; it is also low for
imipenem and meropenem, whereas ertapenem
has a high binding rate of 95%. The elimination
half-life is c. 1 h for all except ertapenem, which
has a half-life of 4 h, permitting once-daily dos-
ing. All carbapenems are widely distributed in the
body and penetrate a broad range of body tissues
and ﬂuids. The usual daily dose for imipenem,
meropenem and panipenem ranges from 1.5 to
3.0 g, depending on the pathogen and the site of
infection. Biapenem was dosed at 300 mg twice-
daily in the Japanese clinical trials; however, in
the Swedish trials the dose selected was 500 mg
three times daily [46].
CLASSIFICATION OF CARBAPENEMS
Based on antimicrobial activity, as well as expe-
rience from clinical use and clinical trials, a
classiﬁcation of carbapenems is proposed
(Table 3) [4]. In comparison to imipenem, me-
ropenem, biapenem and panipenem, ertapenem
is less active against Pseudomonas species and
enterococci, and is thus not indicated in clinical
situations where a nosocomial infection is sus-
pected. Whether the minor differences in activity
against ESBL producers are of clinical relevance
remains to be determined. Owing to its longer
elimination half-life and once-daily dosing regi-
men, ertapenem could be an ideal carbapenem for
the treatment of community-acquired ESBL infec-
tions, whereas the other carbapenems should
Table 2. Pharmacokinetic parameters of the licensed carbapenems after intravenous infusion
Antibiotic Dose (mg) Cmax (mg ⁄L) Half-life (h) Protein binding (%) Urinary recoveryc (%)
Imipenema 500 12–20 0.95 13–20 70
Meropenem 500 23 0.95 10 70
Panipenemb 500 28 1.2 4 30
Biapenem 600 32 1.0 4 60
Ertapenem 1000 155 (i.v.)
67 (i.m.)
4.0 95 38
i.v., intravenous infusion; i.m., intramuscular injection.
aIn combination with cilastatin.
bIn combination with betampiron.
cUnchanged compound.
Table 3. Classiﬁcation of carbapenemsa
Group 1 Group 2 Group 3
Limited activity against non-fermentative
Gram-negative bacilli, suitable for
community-acquired infections
Active also against non-fermentative
Gram-negative bacilli, suitable for
nosocomial infections
In addition to group 2
spectrum, also active against
methicillin-resistant
Staphylococcus aureus
Ertapenem and panipenem Imipenem, meropenem and
biapenem
Doripenem (investigational)
CS-023 (investigational)
aAdapted from [4].
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be used in hospital-acquired infections. Thus,
newer drugs can be easily included in the present
scheme.
CLINICAL EFFICACY OF CARBAPENEMS IN
THE TREATMENT OF INFECTIONS CAUSED
BY ESBL PRODUCERS
Endmiani et al. [47] investigated 35 cases of
bloodstream infections caused by TEM-52 ESBL-
producing K. pneumoniae. Twenty-eight cases
classiﬁed as ‘non-fatal disease’ were investigated
with regard to response to treatment with cipro-
ﬂoxacin or imipenem. Seven strains were resistant
to ciproﬂoxacin in vitro. Ten patients were treated
with imipenem, two of whom failed to respond.
In the ciproﬂoxacin group, only two of seven
patients had even a partial response, and ﬁve
failed, although the bacteria were classiﬁed as
susceptible to ciproﬂoxacin. The authors noted
that the MIC and MBC of ciproﬂoxacin were
markedly inﬂuenced by inoculum, whereas there
was no effect for imipenem (Table 4).
In an international study involving 12 hospitals
in seven countries over a period of 2 years,
Paterson et al. [48] prospectively collected data
on 455 episodes of K. pneumoniae bacteraemia.
Eighty-ﬁve episodes were caused by ESBL-pro-
ducing strains. All strains were susceptible to
imipenem or meropenem; 47% were resistant to
piperacillin–tazobactam, 71% to gentamicin and
19% to ciproﬂoxacin. Treatment with a carbape-
nem (primarily imipenem) was associated with
signiﬁcantly lower 14-day mortality than was
treatment with other in-vitro active antibiotics.
The authors concede that ‘unforeseen bias may
occur in any non-randomised study with a design
similar to ours’ and that ‘optimally, a large, multi-
centre, randomised, controlled trial should be
performed that compares the efﬁcacy of carba-
penems with that of other antibiotic classes. Until
such a trial is performed, we recommend carba-
penems as the therapy of choice for treating
severe infections with ESBL-producing organ-
isms’ [48].
CONCLUSION
Infections caused by ESBL-producing Gram-neg-
ative bacteria complicate therapy and are increas-
ingly reported both in hospitals and in the
community. Antibiotic options are extremely lim-
ited, with carbapenems the treatment of choice for
serious infections. Disturbingly, case of isolates
acquiring resistance under treatment have been
reported. Clinical microbiologists need to be
aware of the subtle differences in in-vitro activity
among the few carbapenems available, though it
has not been determined whether these are of
clinical relevance. In order to preserve this group
of compounds, they should not be used indis-
criminately. Other alternatives, for which very
limited clinical experience is available, are colistin
and tigecycline.
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